Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)

NCT04779242 is registered in ClinicalTrials.gov with Paratek Pharmaceuticals Inc as lead sponsor.

NCT NCT04779242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04779242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)
Lead sponsor
Paratek Pharmaceuticals Inc
Phase
Phase 3
Overall status
Completed
Start date
February 25, 2021
Completion date
March 27, 2024
Enrollment
670 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial pneumonia, community-acquired pneumonia